IL204525A0 - Improved detection of mage -a expression - Google Patents

Improved detection of mage -a expression

Info

Publication number
IL204525A0
IL204525A0 IL204525A IL20452510A IL204525A0 IL 204525 A0 IL204525 A0 IL 204525A0 IL 204525 A IL204525 A IL 204525A IL 20452510 A IL20452510 A IL 20452510A IL 204525 A0 IL204525 A0 IL 204525A0
Authority
IL
Israel
Prior art keywords
mage
expression
improved detection
detection
improved
Prior art date
Application number
IL204525A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Oncomethylome Sciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Oncomethylome Sciences Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL204525A0 publication Critical patent/IL204525A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/30—Oligonucleotides characterised by their secondary structure
    • C12Q2525/301—Hairpin oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL204525A 2007-09-17 2010-03-16 Improved detection of mage -a expression IL204525A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96012807P 2007-09-17 2007-09-17
PCT/GB2008/003142 WO2009037438A1 (en) 2007-09-17 2008-09-17 Improved detection of mage-a expression

Publications (1)

Publication Number Publication Date
IL204525A0 true IL204525A0 (en) 2010-11-30

Family

ID=40239643

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204525A IL204525A0 (en) 2007-09-17 2010-03-16 Improved detection of mage -a expression

Country Status (18)

Country Link
US (4) US9050280B2 (enExample)
EP (2) EP2201131B8 (enExample)
JP (1) JP5406839B2 (enExample)
KR (1) KR20100085917A (enExample)
CN (1) CN101932723B (enExample)
AU (1) AU2008300397A1 (enExample)
BR (1) BRPI0817008A2 (enExample)
CA (2) CA2699856C (enExample)
CO (1) CO6260156A2 (enExample)
CR (1) CR11504A (enExample)
DO (1) DOP2010000076A (enExample)
EA (1) EA017879B1 (enExample)
IL (1) IL204525A0 (enExample)
MA (1) MA31753B1 (enExample)
MX (1) MX2010002965A (enExample)
NZ (2) NZ596545A (enExample)
WO (2) WO2009037438A1 (enExample)
ZA (1) ZA201001878B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130237445A1 (en) * 2010-09-14 2013-09-12 The University Of North Carolina At Chapel Hill Methods and kits for detecting melanoma
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
EP2948566B1 (en) * 2013-01-24 2025-03-26 California Institute of Technology Chromophore-based characterization and detection methods
EP2971179B1 (en) * 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
JP6560336B2 (ja) * 2015-02-26 2019-08-14 株式会社日立ハイテクノロジーズ 核酸分子の構築方法
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
CN105100961B (zh) * 2015-07-23 2018-03-13 华为技术有限公司 视频缩略图生成方法及生成装置
JP6871926B2 (ja) 2015-08-31 2021-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチMayo Foundation for Medical Education and Research 胃の新生物を検出すること
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
DE102016005947B3 (de) 2016-05-16 2017-06-08 Dimo Dietrich Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen
US10294518B2 (en) 2016-09-16 2019-05-21 Fluxion Biosciences, Inc. Methods and systems for ultra-sensitive detection of genomic alterations
US20200010907A1 (en) 2017-03-17 2020-01-09 Mdxhealth Sa Mgmt epigenetic deep-sequencing assay
US20180271710A1 (en) * 2017-03-22 2018-09-27 Bragi GmbH Wireless earpiece for tinnitus therapy
WO2018237327A1 (en) * 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US11441182B2 (en) * 2018-08-08 2022-09-13 Virginia Commonwealth University Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers
CN109540856B (zh) * 2018-11-08 2022-01-28 南京师范大学 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂
CN111551978B (zh) * 2020-05-08 2022-09-27 中国辐射防护研究院 一种放射性土壤样品采样过程不确定度的评定方法
EP4284951A4 (en) * 2021-01-29 2025-05-28 Mayo Foundation for Medical Education and Research DETECTION OF THE PRESENCE OR ABSENCE OF MULTIPLE CANCERS
WO2023108145A1 (en) * 2021-12-10 2023-06-15 Nuprobe Usa, Inc. Universal probes for amplification and detection of nucleic acids
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック, インコーポレイテッド 非メチル化mgmtプロモーターを含む腫瘍を治療する方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6117635A (en) * 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6768000B1 (en) 1998-06-12 2004-07-27 Intergen Company Multi-fluorescent hairpin energy transfer oligonucleotides
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US20040033490A1 (en) * 2000-03-31 2004-02-19 Laird Peter W. Epigenetic sequences for esophageal adenocarcinoma
DE60217837T2 (de) 2001-03-15 2007-10-25 Jacques Schrenzel Nachweis von methicillin-resistenten staphylococcus aureus bakterien (mrsa)
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
WO2003065806A1 (en) 2002-02-04 2003-08-14 Corixa Corporation New immunoeffector compounds
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US7881873B2 (en) * 2003-04-29 2011-02-01 The Jackson Laboratory Systems and methods for statistical genomic DNA based analysis and evaluation
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
DE10338308B4 (de) * 2003-08-15 2006-10-19 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierungen in DNA
WO2005042713A2 (en) * 2003-10-28 2005-05-12 The Johns Hopkins University Quantitative multiplex methylation-specific pcr
US20050130170A1 (en) * 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
WO2006040187A2 (en) * 2004-10-11 2006-04-20 Epigenomics Ag A method for the carry-over protection in dna amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids
US20070059753A1 (en) * 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700374D0 (en) * 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US8911937B2 (en) * 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers

Also Published As

Publication number Publication date
CN101932723B (zh) 2014-09-10
EP2201131B8 (en) 2014-12-10
CN101932723A (zh) 2010-12-29
US20130302363A1 (en) 2013-11-14
WO2009037438A1 (en) 2009-03-26
US8481700B2 (en) 2013-07-09
EP2201131A1 (en) 2010-06-30
CO6260156A2 (es) 2011-03-22
US9050280B2 (en) 2015-06-09
EP2198045A1 (en) 2010-06-23
ZA201001878B (en) 2011-05-25
CR11504A (es) 2011-05-10
EP2201131B1 (en) 2014-11-05
EA017879B1 (ru) 2013-03-29
MX2010002965A (es) 2010-09-14
DOP2010000076A (es) 2010-08-15
US10053724B2 (en) 2018-08-21
US20110287416A1 (en) 2011-11-24
CA2699856A1 (en) 2009-03-26
NZ596545A (en) 2013-05-31
CA2699856C (en) 2019-08-20
US20160032368A1 (en) 2016-02-04
WO2009037441A1 (en) 2009-03-26
AU2008300397A1 (en) 2009-03-26
NZ583796A (en) 2011-12-22
MA31753B1 (fr) 2010-10-01
KR20100085917A (ko) 2010-07-29
US20100280105A1 (en) 2010-11-04
WO2009037438A8 (en) 2010-04-15
JP5406839B2 (ja) 2014-02-05
EA201000334A1 (ru) 2011-02-28
BRPI0817008A2 (pt) 2017-05-16
CA2699853A1 (en) 2009-03-26
JP2010538633A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
ZA201001878B (en) Improved detection of mage-a-expression
GB2456567B (en) Novelty detection
EP2352852A4 (en) DETECTION OF THE CHROMATIN STRUCTURE
EP2276338A4 (en) RECORDING OF MOBILE OBJECTS
GB0708439D0 (en) Position detection
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
GB2459417B (en) Skin detection sensor
GB0816452D0 (en) Isolation detection
EP2257831A4 (en) DETECTION OF AN ENTITY IN MOTION
GB0820309D0 (en) Detection of cancer
ZA200904558B (en) Detection of analytes
EP2130032A4 (en) GONIOMETER
GB0701599D0 (en) Method of detection
ZA201007010B (en) Rapid detection of mycobateria
EP2478364A4 (en) ANTIBODY DETECTION
GB0820899D0 (en) Early detection of sepsis
SG10201406505WA (en) Methods for the detection of fatty-acylated proteins
GB2464965A8 (en) Presence detector
GB0806730D0 (en) Detection of halogens
GB201016732D0 (en) Detection assembly
GB2444777B (en) Detection of radiation
GB0613284D0 (en) Detection of substances
PL382103A1 (pl) Czujnik obecności
GB0918569D0 (en) Computational user-health testing
GB0814289D0 (en) Detector